Overview of mathematical biological models and their application in CML research
|
|
- Abraham Welch
- 5 years ago
- Views:
Transcription
1 Overview of mathematical biological models and their application in CML research March 27 th 2015 Christina Fitzmaurice, MD, MPH Faculty discussants: Vivian Oehler, MD FHCRC/UW William Hazelton, PhD FHCRC Computational Biology Program
2 Outline Definitions and history of mathematical biological models Application in CML Michor model Roeder model Conclusions Future perspectives
3 Definition mathematical biological models Explaining the pathophysiology of a disease using mathematical formulas, which are based on mechanistic understanding of the underlying process NOT purely based on statistical inference Model components have meaningful biological interpretation In contrast STATISTICAL MODELS are not required to have a meaningful biological interpretation Emmers Streib: Frontiers in Genetics 2014
4 Differences between statistical and mathematical models Waller et al: Ecology 2010
5 Historic evolution of mathematical models for cancer 1954 Armitage and Doll Multistage theory of carcinogenesis Incidence curves predict number of mutations required 1971 Knudson Two hit hypothesis for retinoblastoma Two mutations in tumor suppressor gene are necessary for cancer to form 1979 Moolgavkar Two stage clonal expansion model Tumor initiation, clonal expansion, malignant transformation 1991 Loeb Mutator phenotype Mutations in genes that stabilize genome lead to large number of mutations in cancer cells
6 CML mathematical models Despite being a rare disease compared to solid tumors CML has been studied extensively for mathematical models Simple etiology with a known mutation Availability of molecular data (ease of obtaining samples) Availability of successful treatment (TKI)
7 Examples of CML mathematical models Carcinogenesis CML as a model for carcinogenesis (Melo et al: Nat Rev Cancer 2007) Predicting stem cell numbers (Radivoyevitch et al: Math Biosci 1999) Interplay between malignant cells and surrounding environment (Roeder et al: Bull Math Biol 2009) Risk estimation Risk of radiation on CML incidence (Radivoyevitch et al: Radiat Environ Biophys 2001) Gender differences in risk (Radivoyevitch et al: Radiat Environ Biophys 2014) Treatment Cyclic drug treatment/combination of TKIs (Komarova: Math Biosci Eng 2011) Risk for relapse after SCT (Vincent et al: Stem Cells 1999) Risk for relapse after TKI discontinuation (Michor et al: Nature 2005; Foo et al: Plos Comput Biol 2009; Stein et al: Clin Cancer Res 2011; Tang et al: Blood 2011; Tang et al: Haematologica 2012; Horn et al: Blood 2013)
8 MICHOR CML model 2005
9 Mathematical model structure Normal cells Leukemic cells Differentiation rate without imatinib Differentiation rate with imatinib Death rate Stem cells x 0 y 0 d a 0 a' Progenitors x 1 y 1 d 1 b b' Differentiated cells x 2 y 2 d 2 c c Terminally differentiated cells x 3 y 3 d 3 Michor et al, Nature 2005
10 Model equations Michor et al, Nature 2005
11 Mathematical model assumptions BCR/ABL is present in all leukemic cells and leads to slow clonal expansion of leukemic stem cells BCR/ABL leads to increased rate of leukemic cell proliferation compared to normal cells Imatinib reduced the proliferation rate of leukemic stem cells Michor et al, Nature 2005
12 Model fitting and statistical model Measurement of BCR/ABL over BCR ratio in 169 CML patients treated with first line imatinib therapy Biphasic decline in BCR/ABL levels 5% per day 0.8% per day Michor et al, Nature 2005
13 Translation of statistical model results to mathematical model First slope represents turnover of differentiated cells Once differentiated cells have reached steady state with progenitor cells, second slope is decline of progenitor cells 5% per day 0.8% per day Michor et al, Nature 2005
14 Mathematical model results First slope leads to ~1000 fold decline in leukemic cell burden Translates to a 1000 fold reduction of differentiation rate from progenitor cells to differentiated leukemic cells 5% decline per day translates to lifespan of 20 days After ~200 days differentiated cells reach steady state with the progenitor cells and they decrease at the same rate Second slope leads to >7 fold decline in progenitor cell burden 0.8% decline per day this translates to lifespan of 125 days Overall 5000 fold decline in leukemic cell burden Michor et al, Nature 2005
15 Cessation of TKI therapy Imatinib leads to 5000 fold decrease in leukemic cell burden, therefore cessation of therapy should lead to lower levels of BCR/ABL if stem cells had been eradicated by prior therapy HOWEVER, after discontinuation of treatment BCR/ABL increased to pretreatment levels or higher in 3 patients We conclude that leukemic stem cells, which drive CML disease, are not depleted by imatinib therapy Michor et al, Nature 2005
16 Criticism If imatinib does not affect leukemic stem cells this compartment will continue to expand. Clinical long term data is not consistent with this result Model predicted BCR/ABL response under continued imatinib therapy and without resistance Glauche et al, British Journal of Cancer 2007
17 MICHOR CML Model 2011
18 Mathematical model structure Normal cells Leukemic cells Differentiation rate without imatinib Differentiation rate with imatinib Death rate Division rate Stem cells x 0 y 0 d 0 r a a' y,z Progenitors x 1 y 1 d b 1 b' Differentiated cells x 2 y 2 d 2 c c Terminally differentiated cells x 3 y 3 d 3
19 Mathematical model assumptions BCR/ABL is present in all leukemic cells and leads to slow clonal expansion of leukemic stem cells BCR/ABL leads to increased rate of leukemic cell proliferation compared to normal cells Imatinib leads to reduction of differentiation rates in leukemic cells Imatinib possibly reduces the growth rate of cyclic stem cells Michor et al, Blood 2011
20 MODEL FITTING IRIS Trial Newly diagnosed patients treated with imatinib 400 mg qd Inclusion of 22 patients in the model No BCR/ABL measurements for the first 3 months so unable to determine first slope kinetics with IRIS data TIDEL trial Newly diagnosed patients treated with imatinib mg qd Inclusion of 44 patients in the model Initial slope kinetics (1, 2, 3, 6, 9, 12 months data) Michor et al, Blood 2011
21 Biphasic exponential model IRIS data TIDEL data Second slope First slope Second slope Third slope Michor et al, Blood 2011
22 Results for slope and turning point TIDEL data IRIS data Michor et al, Blood 2011
23 Purpose of using biological mathematical model Provision of biological processes explaining observed slope kinetics Able to predict treatment response for different cell compartments
24 Results for mathematical model TIDEL data IRIS data Decline of differentiated cells Decline of progenitor cells Decline of stem cells Michor et al, Blood 2011
25 Results for cell compartments Leukemic cells Normal cells Michor et al, Blood 2011
26 Conclusion Initial slope in IRIS patients is due to decline of progenitor cells, second slope is due to decline in stem cells Analysis was done on highly selected patients who responded to imatinib Michor et al, Blood 2011
27 ROEDER CML Model
28 Mathematical model structure Stem cells exist in 2 different environments (A and Ω) Compartment A: stem cell supporting niche promoting cellular quiescence and regeneration. Compartment Ω: active proliferation a: marker for stemness Leukemic cells have increased proliferation activity Roeder et al, Blood 2013
29 Mathematical model type Stochastic microsimulation of all cells at the single cell level Roeder et al, Blood 2013
30 Mathematical model assumptions TKIs induce an apoptotic effect TKIs inhibit proliferation of leukemic cells Roeder et al, Blood 2013
31 MODEL FITTING German cohort of IRIS Trial Newly diagnosed patients treated with imatinib 400 mg qd Inclusion of 51 patients in the model CML IV trial 280 patients in imatinib 400 mg arm Inclusion of 31 patients (11%) in the model Roeder et al, Blood 2013
32 Statistical model First slope (α) Statistical regression results for 51 IRIS trial patients Second slope (β) Roeder et al, Blood 2013
33 Correlation between first and second slope Roeder et al, Blood 2013
34 Mathematical model fitting Use of results for slope kinetics from statistical model to fit to mathematical model Iterative process to find degradation rate and probability to move to active stem cell compartment for each patient Assumption TKIs induce apoptosis TKIs inhibit leukemic cell proliferation Model estimation Change degradation rate of leukemic cells Change leukemic cell probability to move to active stem cell compartment Roeder et al, Blood 2013
35 Example patient 1 (IRIS trial) Statistical model Mathematical model Roeder et al, Blood 2013
36 Example patient 1 (IRIS trial) End of follow up End of follow up Undetectable BCR/ABL Undetectable BCR/ABL Leukemic stem cell eradication Roeder et al, Blood 2013
37 Results from mathematical model for IRIS trial and CML IV trial Roeder et al, Blood 2013
38 Required follow up time 7 year f/u data form IRIS trial was used Can therapeutic responses be predicted after shorter time period? Need for frequent measurements (6 8 BCR/ABL measurements for each slope) 3 years 4 years 5 years 6 years Full f/u time Roeder et al, Blood 2013
39 Simulation of treatment cessation Simulation of imatinib discontinuation in eligible IRIS Trial patients (MR 5.0 for >2 years) 47 of 51 patients are eligible Of those 47 patients 12 are predicted not to relapse Mathematical model TWISTER trial STIM trial Roeder et al, Blood 2013
40 Cessation simulation 12 patients predicted NOT to relapse 35 patients predicted to relapse Roeder et al, Blood 2013
41 Relationship between slopes and leukemic stem cells Are slope kinetics predictive of stem cell eradication? α/β<16 (=log1.2) predicts no relapse Time on therapy needed until discontinuation is safe: time α/(8 x β) Roeder et al, Blood 2013
42 Prediction of relapse with mathematical model Predicted response Recommended treatment time Individualized approach Conventional approach (2 years in MR 5.0 ) Roeder et al, Blood 2013
43 Conclusion from Roeder Model Confirmation of biphasic BCR/ABL decline Initial slope is due to decline in proliferating leukemic stem cells, second slope is decline in quiescent leukemic stem cells Individualized approach to determine best time for discontinuation of therapy improves probability for long time remission Only applies to responders, does not take into account resistance Roeder et al, Blood 2013
44 Conclusion Models are always wrong and a simplification of biological processes They allow testing of hypotheses that are impossible or difficult to test in vivo/vitro Dependence on assumptions (e.g. treatment effect of TKIs on stem cells, stem cell number, etc.) Models that are clinically relevant need fitting to clinical data Often required advanced mathematical skills need for close collaboration between mathematicians, disease experts (system biology)
45 FUTURE PERSPECTIVES Data from high throughput technology are impossible to understand with conventional methods Rather than focusing on individual genes and proteins mathematical models allow us to evaluate the system Increase in computational power will allow models to become more complex Data mining of electronic health records can add vast amounts of data outside of clinical trials Mathematical models should inform clinical trial design
46 Special thanks to: Vivian Oehler, MD Bill Hazelton, PhD Jerry Radich, MD
47 References Armitage, P. & Doll, R. A two stage theory of carcinogenesis in relation to the age distribution of human cancer. Br. J. Cancer 11, (1957). Emmert Streib, F., Dehmer, M. & Haibe Kains, B. Untangling statistical and biological models to understand network inference: the need for a genomics network ontology. Frontiers in Genetics 5, (2014). Foo, J., Drummond, M. W., Clarkson, B., Holyoake, T. & Michor, F. Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G CSF to imatinib. PLoS Comput. Biol. 5, e (2009). Glauche, I., Horn, M. & Roeder, I. Leukaemia stem cells: hit or miss? Br. J. Cancer 96, ; author reply (2007). Horn, M. et al. Model based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Blood 121, (2013). Knudson, A. G. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. U.S.A. 68, (1971). Komarova, N. L. Mathematical modeling of cyclic treatments of chronic myeloid leukemia. Math Biosci Eng 8, (2011). Loeb, L. A. A mutator phenotype in cancer. Cancer Res. 61, (2001). Melo, J. V. & Barnes, D. J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat. Rev. Cancer 7, (2007). Michor, F. et al. Dynamics of chronic myeloid leukaemia. Nature 435, (2005). Moolgavkar, S. H. & Venzon, D. J. Two event models for carcinogenesis: incidence curves for childhood and adult tumors. Mathematical Biosciences 47, (1979). Radivoyevitch, T., Kozubek, S. & Sachs, R. K. Biologically based risk estimation for radiation induced CML. Inferences from BCR and ABL geometric distributions. Radiat Environ Biophys 40, 1 9 (2001). Radivoyevitch, T., Ramsey, M. J. & Tucker, J. D. Estimation of the target stem cell population size in chronic myeloid leukemogenesis. Radiat Environ Biophys 38, (1999). Radivoyevitch, T. et al. Sex differences in the incidence of chronic myeloid leukemia. Radiat Environ Biophys 53, (2014). Roeder, I., Herberg, M. & Horn, M. An age structured model of hematopoietic stem cell organization with application to chronic myeloid leukemia. Bull. Math. Biol. 71, (2009). Stein, A. M. et al. BCR ABL Transcript Dynamics Support the Hypothesis That Leukemic Stem Cells Are Reduced during Imatinib Treatment. Clinical Cancer Research 17, (2011). Tang, M. et al. Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials. Haematologica 97, (2012). Tang, M. et al. Dynamics of chronic myeloid leukemia response to long term targeted therapy reveal treatment effects on leukemic stem cells. Blood 118, (2011). Vincent, P. C. et al. Relapse in chronic myeloid leukemia after bone marrow transplantation: biomathematical modeling as a new approach to understanding pathogenesis. Stem Cells 17, 9 17 (1999). Waller, L. A. Bridging gaps between statistical and mathematical modeling in ecology. Ecology 91, ; discussion (2010).
48 Additional slides not used during oral presentation
49 Armitage and Doll model M(0)(t): rate of mutation 0 X(t): number of normal (stem) cells at age t I(1): number of cells with 1 mutation I(2): number of cells with 2 mutations M: Malignant tumor Little 2010
50 Problems Experimental data did not support the number of mutations required by this model Next step was a two stage model proposed by Armitage and Doll, inspired by letter from Robert Platt
51 Hornsby et al: Lancet Oncology 2007
52 Clonal evolution hypothesis CML
53 Results from statistical models Exponential model: Biphasic exponential model:
54 Statistical models 1. Exponential model: assumption that leukemic cells decline exponentially 2. Biphasic exponential model: based on the initial observation of biphasic decline TIDEL DATA: R 2 exponential model TIDEL data = 0.81 R 2 biphasic exponential model TIDEL data = 0.98 IRIS DATA: R 2 exponential model = 0.8 R 2 biphasic exponential model = 0.89 Michor et al, Blood 2011
55 Observation that mortality rate of many solid tumors increase with power of age Hypothesis that the power integer translates into the number of ratelimiting steps required for formation of malignant tumor For most solid tumors this relates to 5 7 mutational steps
56 Observations that hereditary and sporadic cases of retinoblastoma could arise form same genetic mechanism with the same mutation rate two hit hypothesis Led to the acceptance of the somatic mutation hypothesis and discovery of tumor suppressor genes
57 Modeling for TKI cessation strategies Modeling stem cell pool to determine safe time for cessation of TKI Current approach in clinical trials STIM/TWISTER trial eligibility: minimum duration of UMRD (no detectable BCR/ABL mrna in any sample tested during the preceding 2 years, whether in peripheral blood (PB) or bone marrow (BM). Requirement of 2 qrt PCR results per year Minimum of 36 months of IM treatment Mahon et al, Lancet Oncology 2010 Ross et al, Blood 2013
Stopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute
Stopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute Natural History of CML Accumulation of immature myeloid cells New cytogenetic changes Chronic Phase Accelerated Phase
More informationChronic Myeloid Leukaemia
Chronic Myeloid Leukaemia Molecular Response: What is really important? Jeff Szer The Royal Melbourne Hospital PROBABILITY, % PROBABILITY OF SURVIVAL AFTER MYELOABLATIVE TRANSPLANTS FOR CML IN CHRONIC
More informationModeling Imatinib-Treated Chronic Myeloid Leukemia
Modeling Imatinib-Treated Chronic Myeloid Leukemia Cara Peters cpeters3@math.umd.edu Advisor: Dr. Doron Levy dlevy@math.umd.edu Department of Mathematics Center for Scientific Computing and Mathematical
More informationStochastic modeling of carcinogenesis
Stochastic modeling of carcinogenesis Rafael Meza Department of Epidemiology University of Michigan SPH-II 5533 rmeza@umich.edu http://www.sph.umich.edu/faculty/rmeza.html Outline Multistage carcinogenesis
More informationABSTRACT APPLYING MATHEMATICAL MODELS TO STUDY THE ROLE OF THE IMMUNE SYSTEM IN CHRONIC MYELOGENOUS LEUKEMIA
ABSTRACT Title of dissertation: APPLYING MATHEMATICAL MODELS TO STUDY THE ROLE OF THE IMMUNE SYSTEM IN CHRONIC MYELOGENOUS LEUKEMIA Geoffrey Douglas Clapp Doctor of Philosophy, 016 Dissertation directed
More informationOxford Style Debate on STOPPING Treatment.
Oxford Style Debate on STOPPING Treatment. This house believes that there are good reasons NOT to stop CML treatment. It should be done within clinical trials, OR only in expert centers where frequent,
More informationLa terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane
La terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane What could be the concept of Cure in CML? Sustained DMR with or without TKI therapy And 100% CML-related survival And QoL comparable
More informationChronic Myeloid Leukemia Outlook: The Future of CML Therapy
Chronic Myeloid Leukemia Outlook: The Future of CML Therapy Neil Shah, MD PhD Edward S. AgenoDistinguished Professor in Hematology/Oncology UCSF School of Medicine San Francisco, California Progression
More informationThe BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine
At the center of advances in hematology and molecular medicine Philadelphia chromosome-positive chronic myeloid leukemia Robert E. Richard MD PhD rrichard@uw.edu robert.richard@va.gov Philadelphia chromosome
More informationCancer develops after somatic mutations overcome the multiple
Genetic variation in cancer predisposition: Mutational decay of a robust genetic control network Steven A. Frank* Department of Ecology and Evolutionary Biology, University of California, Irvine, CA 92697-2525
More informationAn analysis of strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia with imatinib-resistant mutations
An analysis of strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia with imatinib-resistant mutations Dana Paquin a,, David Sacco b, John Shamshoian a a Department
More informationSelection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials
Chronic Myeloid Leukemia Articles and Brief Reports Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials Min Tang, * Jasmine Foo, * Mithat Gönen,
More informationOutlook CML 2016: What is being done on the way to cure
New Horizons 2011 Outlook CML 2016: What is being done on the way to cure Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA CML Working Party
More informationChronic Myeloid Leukemia A Disease of Young at Heart but Not of Body
Chronic Myeloid Leukemia A Disease of Young at Heart but Not of Body Jeffrey H Lipton, PhD MD FRCPC Staff Physician, Princess Margaret Cancer Centre Professor of Medicine University of Toronto POGO November,
More informationStopping Treatment in CML and dose reduction in clinical practice: Can we do it safely? YES WE CAN!
Stopping Treatment in CML and dose reduction in clinical practice: Can we do it safely? YES WE CAN! Dragana Milojković The Hammersmith Hospital, London, UK Leukemic burden Current Aim of TKI therapy Molecular
More informationCML CML CML. tyrosine kinase inhibitor CML. 22 t(9;22)(q34;q11) chronic myeloid leukemia CML ABL. BCR-ABL c- imatinib mesylate CML CML BCR-ABL
1 Key Wordschronic myeloid leukemiaimatinib mesylate tyrosine kinase inhibitor chronic myeloid leukemia CML imatinib mesylate CML CML CML CML Ph 10 1 30 50 3 5 CML α IFNα Ph Ph cytogenetic response CRmajor
More informationMolecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML
Molecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML Imran Mirza, MD, MS, FRCPC Pathology & Laboratory Medicine Institute Sheikh Khalifa Medical City, Abu Dhabi, UAE. imirza@skmc.ae
More informationDati sulla sospensione della terapia
Leucemia Mieloide Cronica Dati sulla sospensione della terapia Gianantonio Rosti, Bologna BCR-ABL Loading in CML Patients 100% 10% 1% MMR MR 4 MR 4.5 STIM study design N=100 Start Imatinib CMR Sustained
More informationModeling imatinib-treated chronic myelogenous leukemia: reducing the complexity of agent-based models
Modeling imatinib-treated chronic myelogenous leukemia: reducing the complexity of agent-based models Peter S. Kim 1 Peter P. Lee 2 Doron Levy 3 September 20, 2007 Abstract We develop a model for describing
More informationStrategic Treatment Interruptions During Imatinib Treatment of Chronic Myelogenous Leukemia
Bull Math Biol (2011) 73: 1082 1100 DOI 10.1007/s11538-010-9553-0 ORIGINAL ARTICLE Strategic Treatment Interruptions During Imatinib Treatment of Chronic Myelogenous Leukemia Dana Paquin Peter S. Kim Peter
More informationarxiv: v1 [q-bio.to] 17 Apr 2016
Optimized Treatment Schedules for Chronic Myeloid Leukemia Qie He 1, Junfeng Zhu 1, David Dingli 2, Jasmine Foo 3**, Kevin Leder 2*, arxiv:1604.04913v1 [q-bio.to] 17 Apr 2016 1 Department of Industrial
More informationMINISYMPOSIUM MATHEMATICAL MODELING OF LEUKEMIA AND MYELOPROLIFERATIVE NEOPLASMS
Tuesday, July 24th, 10:30 MINISYMPOSIUM MATHEMATICAL MODELING OF LEUKEMIA AND MYELOPROLIFERATIVE NEOPLASMS Organizer Morten Andersen Roskilde University Denmark moan@ruc.dk Co-organizer Thomas Stiehl Heidelberg
More informationDynamics and Potential Impact of the Immune Response to Chronic Myelogenous Leukemia
Dynamics and Potential Impact of the Immune Response to Chronic Myelogenous Leukemia Peter S. Kim Laboratoire des Signaux et Systèmes Ecole Supérieure d'electricité 91192 Gif-sur-Yvette France Peter P.
More informationMolecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC
Molecular Markers Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Overview Testing methods Rationale for molecular testing
More informationCancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous
Session8 Medical Genetics Cancer Genetics J avad Jamshidi F a s a U n i v e r s i t y o f M e d i c a l S c i e n c e s, N o v e m b e r 2 0 1 7 What is Cancer? Uncontrolled growth of cells Not all tumors
More information1 Educational session salient points. Tim Hughes, Vivian Oehler and Rick Van Etten. Tim - Imatinib is a less toxic drug than what we are seeing with
1 Educational session salient points. Tim Hughes, Vivian Oehler and Rick Van Etten. Tim - Imatinib is a less toxic drug than what we are seeing with both Nilotinib and Dasatinib. Nilotinib for the cardio
More informationI nuovi guariti? La malattia minima residua nella leucemia mieloide cronica. Fabrizio Pane
I nuovi guariti? La malattia minima residua nella leucemia mieloide cronica Fabrizio Pane What could be the concept of Cure in CML? Sustained DMR with or without TKI therapy And 100% CML-related survival
More informationDynamics of Chronic Myeloid Leukemia Supplementary Online Material
Dynamics of Chronic Myeloid Leukemia Supplementary Online Material Franziska Michor, Timothy P. Hughes, Yoh Iwasa, Susan Branford, Neil P. Shah, Charles L. Sawyers & Martin A. Nowak The basic model. Our
More informationTARGETED THERAPY FOR CHILDHOOD CANCERS
TARGETED THERAPY FOR CHILDHOOD CANCERS AZIZA SHAD, MD AMEY DISTINGUISHED PROFESSOR OF PEDIATRIC HEMATOLOGY ONCOLOGY, BLOOD AND MARROW TRANSPLANTATION LOMBARDI CANCER CENTER GEORGETOWN UNIVERSITY HOSPITAL
More informationMyeloproliferative Disorders - D Savage - 9 Jan 2002
Disease Usual phenotype acute leukemia precursor chronic leukemia low grade lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2
More informationBosulif. Bosulif (bosutinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.22 Section: Prescription Drugs Effective Date: April 1,2018 Subject: Bosulif Page: 1 of 5 Last Review
More informationEffect of Cellular Quiescence on the Success of Targeted CML Therapy
Effect of Cellular Quiescence on the Success of Targeted CML Therapy Natalia L. Komarova 1,2, Dominik Wodarz 1,2 * 1 Department of Mathematics, University of California Irvine, Irvine, California, United
More informationStarting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019
Starting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019 Disclosures Richard A. Larson, MD Research funding to the University
More informationA 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable.
1 Case 1 A 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable. CBC and bone marrow aspiration and biopsy were done. Chromosome study showed she had t(9;22)
More informationSelection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials
Published Ahead of Print on March 14, 2012, as doi:10.3324/haematol.2012.062844. Copyright 2012 Ferrata Storti Foundation. Early Release Paper Selection pressure exerted by imatinib therapy leads to disparate
More informationMP BCR-ABL1 Testing in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia
Medical Policy BCBSA Ref. Policy: 2.04.85 Last Review: 10/18/2018 Effective Date: 10/18/2018 Section: Medicine Related Policies 8.01.30 Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia
More informationFitness Conferred by BCR-ABL Kinase Domain Mutations Determines the Risk of Pre-Existing Resistance in Chronic Myeloid Leukemia
Fitness Conferred by BCR-ABL Kinase Domain Mutations Determines the Risk of Pre-Existing Resistance in Chronic Myeloid Leukemia Kevin Leder 1., Jasmine Foo 2., Brian Skaggs 3, Mercedes Gorre 4, Charles
More informationELN Recommendations on treatment choice and response. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
ELN Recommendations on treatment choice and response Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy ELN 2013 Response to Front-line Treatment Baseline 3 months 6 months OPTIMAL
More informationVenice Meeting Highlights: Key lessons. Conclusions Michele Baccarani Rüdiger Hehlmann
Venice Meeting Highlights: Key lessons Conclusions Michele Baccarani Rüdiger Hehlmann CML therapy in the imatinib era CML prognosis has improved dramatically Cellular and molecular biology studies help
More informationSeptember 20, Submitted electronically to: Cc: To Whom It May Concern:
History Study (NOT-HL-12-147), p. 1 September 20, 2012 Re: Request for Information (RFI): Building a National Resource to Study Myelodysplastic Syndromes (MDS) The MDS Cohort Natural History Study (NOT-HL-12-147).
More informationStudying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (SIMPLICITY)
A service of the U.S. National Institutes of Health Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (SIMPLICITY) This study is currently recruiting participants.
More informationCML: Role of combination treatments, Interferon and immunotherapy in CML
CML: 2017 Role of combination treatments, Interferon and immunotherapy in CML Andreas Burchert Philipps Universität Marburg Universitätsklinikum Gießen und Marburg GmbH Key Developments that will Change
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1 of 6 Last Review Date: March 16, 2018 Tasigna Description Tasigna (nilotinib)
More informationCan ALL be managed without chemotherapy/transplant? (Position: NO) D.Hoelzer J.W.Goethe University Frankfurt
Can ALL be managed without chemotherapy/transplant? (Position: NO) D.Hoelzer J.W.Goethe University Frankfurt Barcelona, September 2012 First report of Monotherapy in childhood ALL 10/16 children with acute
More information[COMPREHENSIVE GENETIC ASSAY PANEL ON
2014 SN GENELAB AND RESEARCH CENTER DR. SALIL VANIAWALA, PH.D [COMPREHENSIVE GENETIC ASSAY PANEL ON MYELOPROLIFERATIVE NEOPLASMS] SN Genelab presents one of the most comprehensive genetic assay panel for
More informationObjectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013
Molecular Markers in Hematologic Malignancy: Ways to locate the needle in the haystack. Objectives Review the types of testing for hematologic malignancies Understand rationale for molecular testing Marcie
More informationMRD in CML (BCR-ABL1)
MRD in CML (BCR-ABL1) Moleculaire Biologie en Cytometrie cursus Barbara Denys LAbo Hematologie UZ Gent 6 mei 2011 2008 Universitair Ziekenhuis Gent 1 Myeloproliferative Neoplasms o WHO classification 2008:
More informationImatinib Mesylate in the Treatment of Chronic Myeloid Leukemia: A Local Experience
ORIGINAL ARTICLE Imatinib Mesylate in the Treatment of Chronic Myeloid Leukemia: A Local Experience PC Bee, MMed*, G G Gan, MRCP*, A Teh, FRCP**, A R Haris, MRCP* *Department of Medicine, Faculty of Medicine,
More informationHOW I TREAT CML. 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek,
HOW I TREAT CML 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek, 12. - 14. april, 2012 Gianantonio Rosti Dpt of Hematology and Oncological Sciences S.
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1of 5 Last Review Date: September 15, 2017 Tasigna Description Tasigna (nilotinib)
More informationImatinib dose intensification, combination therapies. Andreas Hochhaus Universitätsklinikum Jena, Germany
Imatinib dose intensification, combination therapies Andreas Hochhaus Universitätsklinikum Jena, Germany Apperley JF. Lancet Oncol. 2007 High OCT-1 activity is associated with faster MMR in imatinib treated
More information! The Dynamics of Drug Resistance in Cancer
The Dynamics of Drug Resistance in Cancer Doron Levy Department of Mathematics Center for Scientific Computation and Mathematical Modeling University of Maryland, College Park Thanks: NSF, NIH (NCI/NIGMS),
More informationLecture 8 Neoplasia II. Dr. Nabila Hamdi MD, PhD
Lecture 8 Neoplasia II Dr. Nabila Hamdi MD, PhD ILOs Understand the definition of neoplasia. List the classification of neoplasia. Describe the general characters of benign tumors. Understand the nomenclature
More informationThe current standard of care in CML. Gianantonio Rosti, MD University of Bologna Bologna, Italy
The current standard of care in CML Gianantonio Rosti, MD University of Bologna Bologna, Italy CML: Overall Survival 1898-1977 just to remember Clinical Landmarks in CML 1845 1865 1879 1903 1953 1965 1968
More informationCML: Yesterday, Today and Tomorrow. Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center
CML: Yesterday, Today and Tomorrow Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Five Years of Signal Transduction Inhibition The Beginning
More informationFuture of CML: ABL001 and other treatments in the pipeline. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
Future of CML: ABL001 and other treatments in the pipeline. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy Primitive sleeping BCR-ABL-positive leukemic stem cells are less
More informationHow I treat high risck CML
Torino, September 14, 2018 How I treat high risck CML Patrizia Pregno Hematology Dept. Citta della Salute e della Scienza Torino Disclosures Advisory Board: Novartis, Pfizer, Incyte Speaker Honoraria:
More informationEVI-1 oncogene expression predicts survival in chronic phase CML patients resistant to imatinib
EVI-1 oncogene expression predicts survival in chronic phase CML patients resistant to imatinib Mustafa Daghistani Department of Haematology, Imperial College London at Hammersmith Hospital, Du Cane Road,
More informationThe concept of TFR (Treatment Free Remission) in CML
The concept of TFR (Treatment Free Remission) in CML Giuseppe Saglio University of Turin, Italy What can we expect today on long-term therapy with TKIs in CML? German CML study IV Relative and overall
More informationCML HORIZONS 101 AND CML 101
CML HORIZONS 101 AND CML 101 by Pat Garcia-Gonzalez, USA May 1, 2015 Barcelona, Spain Goals of this Session Everything you ever wanted to know and were afraid of asking Help you navigate the conference
More informationEffective Targeting of Quiescent Chronic Myelogenous
Cancer Cell, Volume 7 Supplemental Information Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate Bin Zhang,
More informationImplication of the Autologous Immune System in BCR-ABL Transcript Variations in Chronic Myelogenous Leukemia Patients Treated with Imatinib.
Implication of the Autologous Immune System in BCR-ABL Transcript Variations in Chronic Myelogenous Leukemia Patients Treated with Imatinib. Geoffrey D Clapp, Thomas Lepoutre, Raouf El Cheikh, Samuel Bernard,
More informationTITLE: Properties of Leukemia Stem Cells in a Novel Model of CML Progression to Lymphoid Blast Crisis
AD Award Number: W81XWH-05-1-0608 TITLE: Properties of Leukemia Stem Cells in a Novel Model of CML Progression to Lymphoid Blast Crisis PRINCIPAL INVESTIGATOR: Craig T. Jordan, Ph.D. CONTRACTING ORGANIZATION:
More informationTemplate for Reporting Results of Monitoring Tests for Patients With Chronic Myelogenous Leukemia (BCR-ABL1+)
Template for Reporting Results of Monitoring Tests for Patients With Chronic Myelogenous Leukemia (BCR-ABL1+) Version: CMLBiomarkers 1.0.0.2 Protocol Posting Date: June 2017 This biomarker template is
More informationWelcome and Introductions
Living with Chronic Myeloid Leukemia Welcome and Introductions Living with Chronic Myeloid Leukemia Living with Chronic Myeloid Leukemia (CML) Neil P. Shah, MD, PhD Edward S. Ageno Distinguished Professor
More informationAllogeneic SCT for. 1st TKI. Vienna Austria. Dr. Eduardo Olavarría Complejo Hospitalario de Navarra
The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) Berlin, Germany September 8-11, 2011 Vienna Austria Allogeneic SCT for CML Allogeneic after failure
More informationHematologic and cytogenetic responses of Imatinib Mesylate and significance of Sokal score in chronic myeloid leukemia patients
ORIGINAL ALBANIAN MEDICAL RESEARCH JOURNAL Hematologic and cytogenetic responses of Imatinib Mesylate and significance of Sokal score in chronic myeloid leukemia patients Dorina Roko 1, Anila Babameto-Laku
More informationDynamics and Potential Impact of the Immune Response to Chronic Myelogenous Leukemia
Dynamics and Potential Impact of the Immune Response to Chronic Myelogenous Leukemia Peter S. Kim 1, Peter P. Lee 2 *, Doron Levy 3 * 1 Laboratoire des Signaux et Systèmes, Ecole Supérieure d Electricité,
More informationCharacteristics of Cancer Stem Cells (CSCs)
GENReports: Market & Tech Analysis Characteristics of Cancer Stem Cells (CSCs) > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director Select Biosciences, Inc. enal@selectbio.us! Topic,IntroducEon,and,Scope!
More information9/26/2018. Learning Objectives
ADVANCES IN CHRONIC MYELOID LEUKEMIA Alison Wakoff Loren, MD, MSCE Associate Professor of Medicine Director, Blood & Marrow Transplantation Vice Chair, Faculty Development Department of Medicine Perelman
More informationMathematics and Physics of Cancer: Questions. Robijn Bruinsma, UCLA KITP Colloquium May 6, ) Cancer statistics and the multi-stage model.
Mathematics and Physics of Cancer: Questions Robijn Bruinsma, UCLA KITP Colloquium May 6, 2009 1) Cancer statistics and the multi-stage model. 2) Cancer microevolution and clonal expansion. 3) Metastasis:
More informationChronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2018
Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2018 Disclosures Richard A. Larson, MD Research funding to the University of Chicago: Astellas Celgene Daiichi
More informationPhiladelphia Positive (Ph+) Chronic Myeloid Leukaemia
Advocacy toolkit In this toolkit, we take a look into the treatments for Philadelphia-positive Chronic Myeloid Leukaemia (CML) that have led to treatment free remission (TFR) being one of the biggest topics
More informationCML: definition. CML epidemiology. CML diagnosis. CML: peripheralbloodsmear. Cytogenetic abnormality of CML
MolecularDiagnostic.be Third Scientific Meeting Molecular Diagnostics.be t(9;22) CML: definition Management of CML patients treated with TKI: the place of molecular monitoring Antwerp, December 13 th 11
More informationMolecular monitoring in chronic myeloid leukemia how low can you go?
CHRONIC MYELOID LEUKEMIA Molecular monitoring in chronic myeloid leukemia how low can you go? Susan Branford Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide,
More informationTime slots Sessions Location December 5 th (Friday) Friday Scientific Workshop on Myeloid Development
Overview of CML related sessions at the 56 th ASH Annual Meeting in San Francisco (USA) December 5-9, 2014 Time slots Sessions Location December 5 th (Friday) 13.00-19.15 Friday Scientific Workshop on
More informationCML David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML Current treatment options for CML
1 CML 2012 LLS Jan 26, 2012 David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML 2012 Current treatment options for CML patients Emerging therapies for CML treatment
More informationWhat is New in CML in Hagop Kantarjian, M.D. February 2011
What is New in CML in 2011 Hagop Kantarjian, M.D. February 2011 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis Poor Excellent 10-yr survival 10% 84-90%
More information"Molecular Monitoring Strategies to Track Response to BCR-ABL Kinase Inhibitors in CML"
Association of Molecular Pathology USCAP Companion Meeting Sunday, February 12, 2006 7:00 PM Dan Jones, MD, PhD Associate Professor Medical Director, Molecular Diagnostic Laboratory Division of Pathology
More informationMolecular pathogenesis of CML: Recent insights
Napoli 24 gennaio 2012 Molecular pathogenesis of CML: Recent insights Giuseppe Saglio University of Turin CML Biology CML Clinical practice MILESTONES IN MOLECULAR BIOLOGY OF CML 1960 - Nowell P.C. & Hungerford
More informationMathematical models of chronic lymphocytic leukemia
Mathematical models of chronic lymphocytic leukemia Introduction to CLL Ibrutinib therapy understanding the kinetics Calculating personalized treatments Dominik Wodarz Department of Ecology and Evolutionary
More informationThis information is current as of December 6, 2006
Successful Therapy Must Eradicate Cancer Stem Cells David Dingli and Franziska Michor Stem Cells 2006;24;2603-2610; originally published online Aug 24, 2006; DOI: 10.1634/stemcells.2006-0136 This information
More informationRadiation-induced induced Genomic Instability and Bystander Effects: implications for radiation leukaemogenesis
Radiation-induced induced Genomic Instability and Bystander Effects: implications for radiation leukaemogenesis University of Dundee Medical School Eric G Wright Professor of Experimental Haematology The
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More informationHEMATOPOIETIC CELL TRANSPLANTATION FOR CHRONIC MYELOID LEUKEMIA
LEUKEMIA Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent
More informationEfficiency of carcinogenesis with and without a mutator mutation
Efficiency of carcinogenesis with and without a mutator mutation Robert A. Beckman* and Lawrence A. Loeb *Department of Clinical Research and Development, Hematology Oncology, Centocor, Inc., Malvern,
More information10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD
10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD Dalia Khan 1, Noemi Roy 1, Vasha Bari 1, Grant Vallance 1, Helene Dreau 1, Timothy Littlewood 1, Andrew Peniket 1, Paresh Vyas
More informationONE STEP MULTIPLEX RT-PCR FOR BCRlABL GENE IN MALAY PATIENTS DIAGNOSED AS LEUKAEMIA
ONE STEP MULTIPLEX RT-PCR FOR BCRlABL GENE IN MALAY PATIENTS DIAGNOSED AS LEUKAEMIA 1Rosline H, 1Majdan R, 1Wan Zaidah A, 1Rapiaah M, 1Selamah G, 2A A Baba, 3D M Donald 1Department of Haematology, 2Department
More informationWhen to change therapy? Andreas Hochhaus Universitätsklinikum Jena, Germany
When to change therapy? Andreas Hochhaus Universitätsklinikum Jena, Germany Chromosome 22 Chromosome 9 e1 1b m-bcr M-bcr e1 e2 b1 b5 5 3 BCR ABL 5 3 1a a2 a3 μ -bcr e19 a11 e1a2 b2a2 b3a2 e19a2 p190 bcr-abl
More informationHaematopoietic stem cells
Haematopoietic stem cells Neil P. Rodrigues, DPhil NIH Centre for Biomedical Research Excellence in Stem Cell Biology Boston University School of Medicine neil.rodrigues@imm.ox.ac.uk Haematopoiesis: An
More informationSomatic mutation theories of cancer have been unequivocally
Only three driver gene mutations are required for the development of lung and colorectal cancers Cristian Tomasetti a,b,1, Luigi Marchionni c, Martin A. Nowak d, Giovanni Parmigiani e, and Bert Vogelstein
More informationCML and Future Perspective. Hani Al-Hashmi, MD
CML and Future Perspective Hani Al-Hashmi, MD Objectives Learning from CML history Outcome of interest to clinician Patient and community interest!! Learning from CML history Survival Probability (All
More informationLandes Bioscience Not for distribution.
[Cell Cycle 3:3, 358-362; March 2004]; 2004 Landes Bioscience Report Linear Model of Colon Cancer Initiation Franziska Michor 1 Yoh Iwasa 2 Harith Rajagopalan 3 Christoph Lengauer 3 Martin A. Nowak 1,
More informationAdvancing CML Patient Care: Closing in on a Cure?
J a n u a r y 2 0 0 9 w w w. c l i n i c a l a d v a n c e s. c o m V o l u m e 7, I s s u e 1, S u p p l e m e n t 1 Faculty Francis J. Giles, MB, MD, FRCPI, FRCPath Professor of Medicine Chief, Division
More informationCan chromosomal instability initiate tumorigenesis?
Seminars in Cancer Biology 15 (2005) 43 49 Review Can chromosomal instability initiate tumorigenesis? Franziska Michor a, Yoh Iwasa b, Bert Vogelstein c, Christoph Lengauer c, Martin A. Nowak a, a Program
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationHistory of CML Treatment
History of CML Treatment Eduardo Olavarria No conflict of interest Lisbon, 20th March 2018 #EBMT18 www.ebmt.or What is CML? The mystery of chronic myeloid leukaemia Chronic myeloid leukaemia Often diagnosed
More informationGuidelines and real World: Management of CML in chronic and advanced phases. Carolina Pavlovsky. FUNDALEU May 2017 Frankfurt
Guidelines and real World: Management of CML in chronic and advanced phases Carolina Pavlovsky. FUNDALEU 26-28 May 217 Frankfurt Some Issues in CML 217 First Line treatment: Imatinib vs 2nd generation
More informationStopping treatment how much we understand about mechanisms to stop successfully today, and where are the limits? Andreas Hochhaus
Stopping treatment how much we understand about mechanisms to stop successfully today, and where are the limits? Andreas Hochhaus Frankfurt I 27.5.2017 Aims of CML Therapy Leukemia cells >10 12 CHR 10
More information